Search

Purpose: To explore the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model application for predicting outcome of patients with metastatic renal cell carcinoma using targeted agents. Materials and Methods: We performed a literature review of 989 articles. The selecting process used preferred reporting items for systematic reviews and meta-analyses (PRISMA). All included studies were assessed by Newcastle-Ottawa scale. Results of individual studies were pooled using Stata 14.0 software. Results: A total of 17 articles were included. Most articles provided univariate and multivariate analysis of IMDC model prognosis. Combined HRs were 1.58 (95% CI 1.34-1.82) and 3.74 (95% CI 2.67-4.81) for univariate PFS of intermediate to favorable and poor to favorable respectively. In the category of multivariate PFS, combined HRs were 1.27 (95% CI 0.99-1.56) and 2.29 (95% CI 1.65-2.93) with intermediate to favorable and poor to favorable respectively. Regarding univariate OS, combined HRs were 1.93 (95% CI 1.62-2.24) and 6.25 (95% CI 4.18-8.31) with intermediate to favorable and poor to favorable respectively. With multivariate OS, combined HRs were 1.32 (95%CI 1.04-1.59) and 2.35 (95%CI 1.69-3.01) with intermediate to favorable and poor to favorable respectively. Conclusion: In summary, analysis of currently available clinical evidence indicated that IMDC model could be applied to classify patients with metastatic renal cell carcinoma using targeted agents. However, different types of targeted agents and various areas could affect the accuracy of the model. There was also a difference in predicting patients' PFS and OS.

To investigate the predictors of early postoperative UI after new minimally transurethral procedures dominated by laser therapy for benign prostatic hyperplasia. A literature review of articles published before June 30, 2021 was conducted using the PubMed, Web of Sciences, Cochrane database, and Embase databases. All studies reporting odds ratio (OR) data of prognostic factors in univariable or multivariable analyses were included. The cutoff points of follow-up were within 1 month, at 3 months, and at 6 months. Fourteen studies were identified and assessed for the meta-analysis. The pooled analysis yielded that three prognostic factors related to postoperative urinary incontinence. The pooled OR for age as a continuous variable was 1.066 (95% CI 1.005-1.031) at 3 months, the pooled OR was 3.7 (95% CI 1.276-10.733) for age as a categorical variable within 1 month. The OR for prostate volume was 1.014 (95% CI 1.002-1.026) within 1 month. The pooled OR for prostate volume as a categorical variable was 2.199 (95% CI 1.038-4.659) at 3 months. The OR for resected prostate weight was 1.008 (95% CI 1.001-1.016) within 1 month and the pooled OR for resected prostate weight as a categorical variable was 3.481 (95% CI 1.674-7.239) at 3 months. For patients who have undergone transurethral surgery of prostate using new minimally invasive method, especially laser-based therapy, main factors influencing the development of postoperative UI within 1 month and at 3 months were age, prostate volume, and resected prostate weight.

We discuss the safety and perioperative outcomes of a 2-week interval between prostate biopsy and laparoscopic radical prostatectomy (LRP).We retrospectively reviewed the medical records of 182 patients with prostate cancer (PCa) who underwent transperitoneal LRP 2 weeks after prostate biopsy between 2012 and 2015. We evaluated the following perioperative outcomes: operative time, estimated blood loss (EBL), infection, conversion to open surgery, positive surgery margins (PSM), and complications. We also reviewed studies discussing a shorter interval between biopsy and LRP in peer-reviewed publications.The mean operative time and EBL were 100.2 min and 82.2 ml, respectively. There were no rectal injuries or conversions to open surgery, totally 19 (10.4%) patients experienced complications (Clavien-Dindo Grade I and II): fever occurred in six patients (3.3%), urinary leak in four (2.2%), incomplete paralytic ileus in four (2.2%), deep vein thrombosis in two (1.1%), and postoperative anemia in four. The average bedrest time after surgery was 2.5 days. PSM was detected in twenty-one patients (11.5%) . 167 patients (91.7%) recovered continence.Follow-up ranged from 13-37 months, the biochemical recurrence (BCR) rate was 10.4% (19/182).The seven peer-reviewed studies we reviewed that a shorter interval was safe and did not influence surgical outcomes.Our study shows that a 2-week interval between biopsy and LRP is safe and does not negatively affect surgical outcomes.

We aimed to summarize and clarify the association between cytochrome P450 17α-hydrolase (CYP17A1) polymorphisms and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone. The databases of PubMed, EMBASE, and Web of Science were searched for relevant studies. Overall survival (OS) and/or progression-free survival (PFS) were calculated. Odds ratios (ORs) and/or hazard ratios (HRs) with 95% confidence interval (CI) were utilized to evaluate the strength of the association. A total of 3 studies including 204 patients were analyzed in this systematic review. It was shown that CYP17A1 copy number variations were related to the prognosis of mCRPC patients treated with abiraterone. In addition, rs2486758, a common single-nucleotide polymorphisms (SNPs) in CYP17A1, was significantly associated with a poor biochemical response and a faster biochemical progression. Our systematic review showed that CYP17A1 polymorphisms are associated with response to abiraterone in mCRPC patients. Further research is needed to translate these findings into clinical decisive parameters.